^
BIOMARKER:
KRAS G12C
i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
›
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib Sensitive: A1 - Approval
Amgen Press Release - 1 week
|
sotorasib Sensitive: A1 - Approval
Amgen Press Release - 1 week
|
KRAS G12C
|
Gastrointestinal Cancer
|
KRAS G12C
|
Gastrointestinal Cancer
|
MRTX849 Sensitive: C2 – Inclusion Criteria
ASCO-GI 2022 - 1 week
|
MRTX849 Sensitive: C2 – Inclusion Criteria
ASCO-GI 2022 - 1 week
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
MRTX849 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
MRTX849 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
MRTX849 Sensitive: B - Late Trials
|
MRTX849 Sensitive: B - Late Trials
|
KRAS G12C
|
Lung Non-Squamous Non-Small Cell Cancer
|
KRAS G12C
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
abemaciclib Sensitive: B - Late Trials
|
abemaciclib Sensitive: B - Late Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
cetuximab Resistant: B - Late Trials
|
cetuximab Resistant: B - Late Trials
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
panitumumab Resistant: B - Late Trials
|
panitumumab Resistant: B - Late Trials
|
KRAS G12C
|
Ampulla of Vater Carcinoma
|
KRAS G12C
|
Ampulla of Vater Carcinoma
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KRAS G12C
|
Pancreatic Cancer
|
KRAS G12C
|
Pancreatic Cancer
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KRAS G12C
|
Melanoma
|
KRAS G12C
|
Melanoma
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KRAS G12C
|
Endometrial Cancer
|
KRAS G12C
|
Endometrial Cancer
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KRAS G12C
|
Gastrointestinal Cancer
|
KRAS G12C
|
Gastrointestinal Cancer
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
MRTX849 Sensitive: C2 – Inclusion Criteria
|
MRTX849 Sensitive: C2 – Inclusion Criteria
|
KRAS G12C
|
Solid Tumor
|
KRAS G12C
|
Solid Tumor
|
D-1553 Sensitive: C2 – Inclusion Criteria
|
D-1553 Sensitive: C2 – Inclusion Criteria
|
KRAS G12C
|
Lung Cancer
|
KRAS G12C
|
Lung Cancer
|
D-1553 Sensitive: C2 – Inclusion Criteria
|
D-1553 Sensitive: C2 – Inclusion Criteria
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria
|
MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
SAR442720 Sensitive: C2 – Inclusion Criteria
|
SAR442720 Sensitive: C2 – Inclusion Criteria
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
KRAS G12C
|
Cholangiocarcinoma
|
KRAS G12C
|
Cholangiocarcinoma
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
KRAS G12C
|
Ovarian Cancer
|
KRAS G12C
|
Ovarian Cancer
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
KRAS G12C
|
Pancreatic Cancer
|
KRAS G12C
|
Pancreatic Cancer
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
KRAS G12C
|
Endometrial Cancer
|
KRAS G12C
|
Endometrial Cancer
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
cetuximab + MRTX849 Sensitive: C3 – Early Trials
|
cetuximab + MRTX849 Sensitive: C3 – Early Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
KRAS G12C
|
Solid Tumor
|
KRAS G12C
|
Solid Tumor
|
IN10018 + MRTX1257 Sensitive: C3 – Early Trials
|
IN10018 + MRTX1257 Sensitive: C3 – Early Trials
|
KRAS G12C
|
HCC
|
KRAS G12C
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
KRAS G12C
|
Gastrointestinal Cancer
|
KRAS G12C
|
Gastrointestinal Cancer
|
sotorasib + AbGn-107 Sensitive: C3 – Early Trials
|
sotorasib + AbGn-107 Sensitive: C3 – Early Trials
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
panitumumab + sotorasib Sensitive: C3 – Early Trials
|
panitumumab + sotorasib Sensitive: C3 – Early Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
lorlatinib Resistant: C3 – Early Trials
|
lorlatinib Resistant: C3 – Early Trials
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
bevacizumab Resistant: C3 – Early Trials
|
bevacizumab Resistant: C3 – Early Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
KRAS G12C
|
LUAD
|
KRAS G12C
|
LUAD
|
MRTX849 + TVB-3664 Sensitive: D – Preclinical
|
MRTX849 + TVB-3664 Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Cancer
|
KRAS G12C
|
Pancreatic Cancer
|
sotorasib + VRx-510 Sensitive: D – Preclinical
|
sotorasib + VRx-510 Sensitive: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + VRx-510 Sensitive: D – Preclinical
|
sotorasib + VRx-510 Sensitive: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + TPX-0005 Sensitive: D – Preclinical
|
sotorasib + TPX-0005 Sensitive: D – Preclinical
|
KRAS G12C
|
Solid Tumor
|
KRAS G12C
|
Solid Tumor
|
sotorasib + IN10018 Sensitive: D – Preclinical
|
sotorasib + IN10018 Sensitive: D – Preclinical
|
KRAS G12C
|
Solid Tumor
|
KRAS G12C
|
Solid Tumor
|
PD-0325901 + BGB-283 Sensitive: D – Preclinical
|
PD-0325901 + BGB-283 Sensitive: D – Preclinical
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
regorafenib Resistant: D – Preclinical
|
regorafenib Resistant: D – Preclinical
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
sunitinib Resistant: D – Preclinical
|
sunitinib Resistant: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + MRTX849 + VS-6766 Sensitive: D – Preclinical
|
sotorasib + MRTX849 + VS-6766 Sensitive: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + VS-6766 Sensitive: D – Preclinical
|
sotorasib + VS-6766 Sensitive: D – Preclinical
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
sotorasib + MRTX849 + VS-6766 Sensitive: D – Preclinical
|
sotorasib + MRTX849 + VS-6766 Sensitive: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical
|
sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
selinexor + MRTX1257 Sensitive: D – Preclinical
|
selinexor + MRTX1257 Sensitive: D – Preclinical
|
KRAS G12C
|
Lung Cancer
|
KRAS G12C
|
Lung Cancer
|
afatinib + sotorasib Sensitive: D – Preclinical
|
afatinib + sotorasib Sensitive: D – Preclinical
|
KRAS G12C
|
Lung Cancer
|
KRAS G12C
|
Lung Cancer
|
sotorasib + RMC-4550 Sensitive: D – Preclinical
|
sotorasib + RMC-4550 Sensitive: D – Preclinical
|
KRAS G12C
|
Lung Cancer
|
KRAS G12C
|
Lung Cancer
|
palbociclib + sotorasib Sensitive: D – Preclinical
|
palbociclib + sotorasib Sensitive: D – Preclinical
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
D-1553 Sensitive: D – Preclinical
|
D-1553 Sensitive: D – Preclinical
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + selinexor Sensitive: D – Preclinical
|
sotorasib + selinexor Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
sotorasib + selinexor Sensitive: D – Preclinical
|
sotorasib + selinexor Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
selinexor + MRTX1257 Sensitive: D – Preclinical
|
selinexor + MRTX1257 Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Cancer
|
KRAS G12C
|
Pancreatic Cancer
|
D-1553 Sensitive: D – Preclinical
|
D-1553 Sensitive: D – Preclinical
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
trametinib + panitumumab + sotorasib Sensitive: D – Preclinical
|
trametinib + panitumumab + sotorasib Sensitive: D – Preclinical
|
KRAS G12C
|
CRC
|
KRAS G12C
|
CRC
|
trametinib + sotorasib Sensitive: D – Preclinical
|
trametinib + sotorasib Sensitive: D – Preclinical
|
KRAS G12C
|
Pancreatic Adenocarcinoma
|
KRAS G12C
|
Pancreatic Adenocarcinoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
